The IC50 of DZNep in cell lines and 16 AML patients with clinical characteristics
| U. Pt no. and cell lines . | Age, y/sex . | FAB subtype . | Karyotype . | MLL rearrangement . | FLT3-ITD . | FLT3-TKD . | DZNep IC50, μM . |
|---|---|---|---|---|---|---|---|
| 1 | 34/F | M5a | N | Neg | ND | ND | 8.1 |
| 2 | 68/M | M1/M5 | +11 | Neg | Neg | Neg | 12.0 |
| 3 | 28/M | M1 | +5p15 | Pos | Neg | Neg | 9.5 |
| 4 | 68/F | M1 | −13q21 | Pos | Neg | Neg | 11.5 |
| 5 | 36/M | M2 | N | Neg | Neg | Pos | 7.0 |
| 6 | 37/F | M5 | N | Neg | Neg | Pos | 6.0 |
| 7 | 39/M | M1 | t(6;9)(p23;q34) | Neg | Pos | Neg | 5.2 |
| 8 | 69/F | M1 | t(9;22)(q34;q11), +8, +19 | Neg | Neg | Neg | 15.0 |
| 9 | 33/F | M4 | inv(16)(p13q22) | Neg | ND | ND | 12.9 |
| 10 | 68/F | M2 | N | Neg | ND | Neg | 9.3 |
| 11 | 56/M | ND | t(9;22)(q34;q11), +8p22, −15, −18 | Neg | Neg | Neg | 14.8 |
| 12 | 58/F | M4 | N | Neg | ND | ND | 10.0 |
| 13 | 43/M | M2 | t(8;21)(q22;q22) | Neg | Neg | Neg | 3.7 |
| 14 | 49/M | ND | ND | ND | Pos | Neg | 3.5 |
| 15 | 42/F | M1 | N | Neg | Pos | Neg | 4.6 |
| 16 | 59/F | M2 | N | Neg | ND | ND | 5.8 |
| MOLM-14 | NA | M5 | +6, +8, ins(11;9)(q23;p22p23 | Pos | Pos | Neg | 4.2 |
| MV4–11 | NA | M5 | +8, +19, t(4;11)(q21;q23) | Pos | Pos | Neg | 6.3 |
| Kasumi-1 | NA | M2 | t(8:21)(q22;q22) | Neg | Neg | Neg | 4.8 |
| TF-1 | NA | M6 | Hyperdiploid | Neg | Neg | Neg | 12.5 |
| Mono-Mac-1 | NA | M5 | t(9;11)(p22;q23) | Pos | Neg | Neg | 15.0 |
| THP-1 | NA | M5 | t(9;11)(p22;q23) | Pos | Neg | Neg | Resistant |
| KG-1 | NA | M1 | Hypodiploid | Neg | Neg | Neg | Resistant |
| U. Pt no. and cell lines . | Age, y/sex . | FAB subtype . | Karyotype . | MLL rearrangement . | FLT3-ITD . | FLT3-TKD . | DZNep IC50, μM . |
|---|---|---|---|---|---|---|---|
| 1 | 34/F | M5a | N | Neg | ND | ND | 8.1 |
| 2 | 68/M | M1/M5 | +11 | Neg | Neg | Neg | 12.0 |
| 3 | 28/M | M1 | +5p15 | Pos | Neg | Neg | 9.5 |
| 4 | 68/F | M1 | −13q21 | Pos | Neg | Neg | 11.5 |
| 5 | 36/M | M2 | N | Neg | Neg | Pos | 7.0 |
| 6 | 37/F | M5 | N | Neg | Neg | Pos | 6.0 |
| 7 | 39/M | M1 | t(6;9)(p23;q34) | Neg | Pos | Neg | 5.2 |
| 8 | 69/F | M1 | t(9;22)(q34;q11), +8, +19 | Neg | Neg | Neg | 15.0 |
| 9 | 33/F | M4 | inv(16)(p13q22) | Neg | ND | ND | 12.9 |
| 10 | 68/F | M2 | N | Neg | ND | Neg | 9.3 |
| 11 | 56/M | ND | t(9;22)(q34;q11), +8p22, −15, −18 | Neg | Neg | Neg | 14.8 |
| 12 | 58/F | M4 | N | Neg | ND | ND | 10.0 |
| 13 | 43/M | M2 | t(8;21)(q22;q22) | Neg | Neg | Neg | 3.7 |
| 14 | 49/M | ND | ND | ND | Pos | Neg | 3.5 |
| 15 | 42/F | M1 | N | Neg | Pos | Neg | 4.6 |
| 16 | 59/F | M2 | N | Neg | ND | ND | 5.8 |
| MOLM-14 | NA | M5 | +6, +8, ins(11;9)(q23;p22p23 | Pos | Pos | Neg | 4.2 |
| MV4–11 | NA | M5 | +8, +19, t(4;11)(q21;q23) | Pos | Pos | Neg | 6.3 |
| Kasumi-1 | NA | M2 | t(8:21)(q22;q22) | Neg | Neg | Neg | 4.8 |
| TF-1 | NA | M6 | Hyperdiploid | Neg | Neg | Neg | 12.5 |
| Mono-Mac-1 | NA | M5 | t(9;11)(p22;q23) | Pos | Neg | Neg | 15.0 |
| THP-1 | NA | M5 | t(9;11)(p22;q23) | Pos | Neg | Neg | Resistant |
| KG-1 | NA | M1 | Hypodiploid | Neg | Neg | Neg | Resistant |
AML indicates acute myeloid leukemia; U. Pt no., unique patient number; FAB, French-American-British; N, normal karyotype; MLL, mixed lineage leukemia gene; FLT3, FMS-like tyrosine kinase 3; ITD, internal tandem duplication; TKD, tyrosine kinase domain mutation; NA, not applicable; ND, not done; Neg, negative; and Pos, positive.